MTIC

• UNSPSC Description:

  MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity [1][2][3][4].

• Target Antigen:

  Drug Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mtic.html

• Purity:

  99.51

• Solubility:

  DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C1=C(/N=N/NC)N=CN1)N

• Molecular Weight:

  168.16

• References & Citations:

  [1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Nagasawa HT, et al. The mechanism of alkylation of DNA by 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388). Non-involvement of diazomethane. Chem Biol Interact. 1974 Jun;8(6):403-13.|[3]Tsang LL, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27(5):342-6.|[4]Beal DD, et al. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats. J Natl Cancer Inst. 1975 Apr;54(4):951-7.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  3413-72-7